Abstract
Denosumab is a perfect example on the targeted anticancer therapy. The inhibition of RANKL activity suppressed the osteoclasts’ resorptive function and so prevented skeletal related events. This effect is useful not only against bone metastases, but also in the treatment of other diseases caused by bone loss. In different solid tumors with bone metastasis the quality of life also improved, although the overall survival usually showed no change. On the market the main competitors for denosumab are still the bisphosphonates (questions of costs and reimbursement are not discussed) and some potential new agents e.g. Src kinases (as dasatinib, saracatinib, bosutinib), cathepsin K inhibitors, (e.g. odanacatib), and new selective estrogen receptor modulators (e.g. bazedoxifene, lasofoxifene). Nevertheless, today denosumab is one of the most powerful agents in bone-saving area.
Similar content being viewed by others
References
Baron R, Ferrari S, Russel RGG (2011) Denosumab and bisphosphonates: Different mechanisms of action and effects. Bone 48:677–692
Brown JE, Coleman RE (2011) Denosumab in patients with cancer—a surgical strike against the osteoclast. Nature Rev Clin Oncol 9:110–118
Martin T, Gooi JH, Sims NA (2009) Molecular mechanisms in coupling of bone formation to resorption. Crit Rev Eukaryot Gene Expr 19:73–88
Bruzzaniti A, Baron R (2006) Molecular regulation of osteoclast activity. Rev J Endocr Metab Disord 7:123–139
Theoleyre S, Wittrant Y, Tat SK et al (2004) The molecular triad OPR/RANK/RANKL involvement in the orchestration of pathophysiological bone remodeling. Cytokine Growth Factor Rev 15:457–475
Weight HL, McCarthy HS, Middleton J, Marshall MJ (2009) RANK, RANKL, and osteoprotegerin in bone biology and disease. Curr Rev Musculoskelet Med 2:56–64
Pederson L, Ruan M, Wetendorf JJ et al (2008) Regulation of bone formationby osteoclasts involvesWnt/BMP signaling and the chemokine sphingosine-1-phosphate. Proc Natl Acad Sci USA 105:20764–20769
Sims N (2010) EPHs and ephrins: many pathways to regulate osteoblasts and osteoclasts. IBMS BoneKEy 7:304–313
Dougall WC, Chaisson M (2006) The RANK/RANKL/OPG triad in cancer induced bone diseases. Cancer Metast Rev 25:541–549
Akiyama T, Choong PF, Dass CR (2010) RANK-Fc inhibits malignancy via inhibiting ERK activation and evoking caspase3-mediated anoikis in human osteosarcoma cells. Clin Exp Metast 27:207–215
Akiyama T et al (2010) Systemic RANK-Fc protein therapy is efficacious against primary osteosarcoma growth in murine model via activity against osteoclasts. J Pharm Pharmacol 62:470–476
Russell RG, Watts NB, Ebetino FH, Rogers MJ (2008) Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 19:733–759
Kostenuik P, Nguyen HG, McCabe J et al (2009) Denosumab, a fully human monoclonal antibody to RNAKL inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL. J Bone Miner Res 24:182–195
Weinstein RS, Roberson PK, Manolagas SC (2009) Giant osteoclast formation and long-term oral bisphosphonate therapy. N Engl J Med 360:53–62
Bekker PJ, Holloway DI, Rasmussen AS et al (2004) A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res 19:1059–1066
Lin JH (1996) Bisphosphonates: a review of their pharmacokinetic properties. Bone 18:85–95
Cremers S, Sparidqans R et al (2002) A pharmacokinetic and pharmacodynamic model for intravenous bisphosphonate (pamidronate) in osteoporosis. Eur J Clin Pharmacol 57:883–8890
Body JJ et al (2003) A phase I study of ANGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer 97(Suppl 3):887–892
Body JJ et al (2006) Study of the biological receptor activator of nuclear factor kB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res 12:1221–1228
Lipton A et al (2007) Randomized, active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases. J Clin Oncol 25:4431–4437
Ellis GK et al (2008) Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for non-metastatic breast cancer. J Clin Oncol 26:4875–4882
Shahinian VB, Kuo YF, Freeman JL, Goodwin JS (2005) Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 352:154–164
Smith MR et al (2006) Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer. J Urol 136–139
Smith MR et al (2009) Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 361:745–755
Smith MR et al Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase III, randomized, placebo-controlled trial. Lancet. doi:10.1016/S0140-6736(11)61226-9
Brodowitz T, O’Byrne K, Manegold C Bone matters in lung cancer. Ann Oncol. doi:10.1093/annoncol/mds009
Fizazi K et al (2009) Randomized phase II trial of denosunab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol 27:1564–1571
Fizazi K, Carducci M, Smith M et al (2011) Denosumab versus zoledronic acid for the treatment of bone metastases in men with castration-resistant prostate cancer. A randomised, double-blind study. The Lancet 377:813–822
Stopeck AT, Lipton A, Body J-J et al (2010) Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 28:5132–5139
Henry DH et al (2011) A randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastasis in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 29:1125–1132
Huang L, Xu J, Wood DJ, Zheng MH (2000) Gene expression of osteoprotegerin ligand, osteoprotegerin, and receptor activator of NF-kB in giant cell tumour of bone: possible involvement in tumour-cell induced osteoclast-like cell formation. Am J Pathol 156:761–767
Thomas D, Henshaw R, Skubicz K et al (2010) Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study. Lancet Oncol 11:275–280
Saylor PJ (2011) Denosumab –a new option for solid tumors metastatic to bone. Nature Rev Clin Oncol 8:322–324
Hofbauer LC, Rachner DT, Harnann C (2011) From bone to breast and back—the bone cytokine RANKL and breast cancer. Breast Cancer Rev 13:107–108
Smith MR, Sand F, Colemann R et al (2012) Denosumab and bone-metastasis-free survival in men with castration-rersistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. The Lancet 379:3946
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kopper, L. Denosumab—A Powerful RANKL Inhibitor to Stop Lytic Metastases and Other Bone Loss Actions by Osteoclasts. Pathol. Oncol. Res. 18, 743–747 (2012). https://doi.org/10.1007/s12253-012-9538-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12253-012-9538-4